| 000 | 01783 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518015213.0 | ||
| 264 | 0 | _c20200728 | |
| 008 | 202007s 0 0 eng d | ||
| 022 | _a1029-2403 | ||
| 024 | 7 |
_a10.1080/10428194.2018.1562185 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFournier, Elise | |
| 245 | 0 | 0 |
_aIncreased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _c07 2019 |
||
| 300 |
_a1827-1830 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAntigens, CD19 _ximmunology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Rearrangement |
| 650 | 0 | 4 |
_aHistone-Lysine N-Methyltransferase _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xchemically induced |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyeloid-Lymphoid Leukemia Protein _xgenetics |
| 650 | 0 | 4 |
_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy |
| 650 | 0 | 4 | _aPrognosis |
| 700 | 1 | _aInchiappa, Luca | |
| 700 | 1 | _aDelattre, Carole | |
| 700 | 1 | _aPignon, Jean-Michel | |
| 700 | 1 | _aDanicourt, Frédérique | |
| 700 | 1 | _aBemba, Maxime | |
| 700 | 1 | _aRoche-Lestienne, Catherine | |
| 700 | 1 | _aDaudignon, Agnès | |
| 700 | 1 | _aDecool, Gauthier | |
| 700 | 1 | _aRoumier, Christophe | |
| 700 | 1 | _aDumezy, Florent | |
| 700 | 1 | _aFournier, Loïc | |
| 700 | 1 | _aGrardel, Nathalie | |
| 700 | 1 | _aPreudhomme, Claude | |
| 700 | 1 | _aDuployez, Nicolas | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 60 _gno. 7 _gp. 1827-1830 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/10428194.2018.1562185 _zAvailable from publisher's website |
| 999 |
_c29227939 _d29227939 |
||